1Garbe C, Peris K, Hauschild A, et al. Diagnosis and treatment of melanoma : European consensus-based interdisciplinary guideline [ J ]. Eur J Cancer, 2010,46 (2) :270 -283.
2Balch CM, Soong SJ, Gershenwald JE, et al. Prognostic factors analysis of 17,600 melanoma patients : validation of the American Joint Committee on Cancer melanoma staging system [J]. J Clin Oncol,2001,15 ; 19(16) :3622 - 3634.
3Lui P, Cashin R, Machado M, et al. Treatments for metastatic melanoma : synthesis of evidence from randomized trials [ J ]. Cancer Treat Rev, 2007,33 ( 8 ) : 665 - 680.
4Chapman PB, Einhorn LH, Meyers ML, et al. Phase Ⅲ multicenter randomized trial of the Dartmouth regimen versus daearbazine in patients with metastatic melanoma [ J ]. Clin Cancer Res, 1999,5 (6) : 1319 - 1323.
5Atkins MB, Lotze MT, Dutcher JP, et al. High-dose recombinant i nterleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993 [J]. J Clin Oncol,1999,17(7) : 2105 -2116.
7Atkins MB, Hsu J, Lee S, et al. Phase Ⅲ trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial coordinated by the Eastern Cooperative Oncology Group [J]. J Clin Oncol,2008,26 (35) :5748 - 5754.
8Ives NJ, Stowe RL, Lorigan P, et al. Chemotherapy compared with biochemotherapy for the treatment of metastatic melanoma: a meta analysis of 18 trials involving 2,621 patients [ J ]. J Clin Oncol, 2007,25 (34) :5426 - 5434.
9Davies H, Bignell GR, Cox C, Nature. Mutations of the BRAF gene in human cancer [ J]. 2002,417 (6892) :949 - 954.
4Barth A, Wanek LA, Morton DL. Prognostic factors in 1 521 melanoma patients with distant metastases[J].J Am Coll Surg,1995, 181 (3) :263 -265.
5Middleton M, Groh J, Aarouson N, et al. Randomized phase Ⅲ study of temozolomide: dacarbazine in the treatment of patients with advanced metastatic malignant melanoma [J]. J Clin Oncol, 2000, 18:158 - 166.
6Avril MF, Aamdal S, Grob JJ, et al. Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase Ⅲ study[J]. J clin Oncol, 2004,22:1118-1125.
7Bedikian AY, Millward M, Pehamberger H, et al. Bet-2 anti sense( oblimersen sodium) plus daearhazine in patients with ad ranted melanoma : the Oblimersen Melanoma Study Group [ J ] J Clin Oneol, 2006, 24:4738 -4745
8Rossi CR, Lejeune F J, Pontes L, et al. Phase Ⅰ-Ⅱ study on isolation antiblastie fotemustine perfusion after dacarbazine chemosensitization for advanced melanoma of the extremities [ J ]. Melanoma Res,2003,13 : 293 - 297.
9Shiehiri M, Hirata Y. Antianginngenesis signals by endo statin [J]. FASEB J,2001,15(6) :1044 -1053.
10Huang X, Wong MK, Zhao Q el al. Soluble recombinant endostatin purifiled frum Escherichia eoli: antiangiogenic act IV ity and antitumor effect [ J ]. Cancer Res, 2001 , 61 ( 2 ) : 478-481
2Roberts PJ, Der CJ. Targting the Raf-MEK-ERK mitogen-activated protein kinase for the treatment of cancer! J l. ()ncogene, 2007,26 (22) :3291 -3310.
3Li Q, Wu J ,Zheng H ,et al. Discovery of 3-( 2-aminoethyl ) -5-( 3-phcn-yl-propylidene) -thiazolidine- 2,4-dione as a dual inhibitor of the Raf/ MEK/ERK and the PI3K/Akt signaling pathways[J]. Bioorganic & Medicinal Chemistry" Letters ,2010,20 ( 15 ) :4526 - 4530.
4Olivier S,Robe P,Bours V. Can NF-kB be a target for novel and effi- cient anti-cancer agents ? [ J ]. Biochem Pharmacol, 2006,72 ( 9 ) : 1054 - 1068.
5Mouawad R, Sebert M, Michels J, et al. Treatment for metastatic malig- nant melanoma:Old drugs and new strategies [ J ]. Critical Reviews in Oncology/Hematology,2010,74 ( 1 ) :27 - 39.
6Ji Z, Flaherty KT, Tsao H, et al. Targeting the RAS pathway in melano- ma [ J ]. Trends in Molecular Medicine,2012,18 ( 1 ) :27 - 33.
7Ji Z,Flaherty KT,Tsao H. Molecular therapeutic approaches to melano- ma [ J ]. Molecular Aspects of Medicine,2010,31 (2) : 194 - 204.
8Fukazawa H, Noguchi K, Murakami Y, et al. Mitogen-activated protein/ extrace|lular signal- regulated kinase kinase (MEK) inhibitors restore anoikis sensilivity in human breast cancer cell lines with a constitutive- ly activated extracellular-regulated kinase (ERK) pathway [ J ]. Mol Cancer Ther,2002, l (5) : 303 - 309.
9Lind CR, Gray CW, Person AG, et al. The mitogen-activated/extracel- lularsigrtal-regulated kinasse kinaset/2 inhibitor U0126 induces glial fibrillary acidic protein expression and reduces the proliferation and migration of C6 glioma cells [ J ]. Neuroscience ,2006,141 (4) : 1925 - 1933.
10Tsubaki M, Satan T, hob T,et al. Reduction of metastasis, cell inva- sion, and adhesion in mouse osteosarcoma by YM529/ONO-5920-in- duced blockade of the Ras/MEK/ERK and Ras/PI3K/Akt pathway [J]. Toxicol Appl Phamlacol,2012,259 (3) :402 -410.
